Literature DB >> 23885329

Potent suppression of arginase 1 expression in murine macrophages by low dose endotoxin.

Michael J Surace1, Liwu Li.   

Abstract

Macrophages can respond to diverse signals and adopt multiple phenotypes. Although interleukin-4 (IL-4) is shown to potently induce the expression of arginase 1 and contribute to differentiation of macrophages to the anti-inflammatory M2 phenotype, other modulators may potentiate or reduce the effect of IL-4. In this report, we focus on the combinatorial effects of IL-4 with all-trans retinoic acid (ATRA) and lipopolysaccharide (LPS). ATRA has been shown to contribute to the resolution of inflammation, however it has not been linked to arginase 1 expression in macrophages. We demonstrate that although ATRA alone has no effect on the expression or activities of arginase 1, ATRA can dramatically potentiate the induction of arginase 1 by IL-4. On the other hand, high doses of LPS, such as those seen in septic shock, can induce the expression of both M1 and M2 mediators in macrophages. The effects of subclinical doses of LPS, which are prevalent in humans with adverse health conditions, on macrophage differentiation are not well studied. We demonstrate that low dose LPS can effectively suppress the expression of arginase 1 induced by IL-4 and ATRA. Mechanistically, we report that the interleukin-1 receptor-associated kinase 1 (IRAK-1) and Toll-interacting-protein (Tollip) are involved in the suppressive effect of low dose LPS. Our study reveals dynamic modulation of arginase 1 expression in macrophages by competing agonists, and bears relevance for potential intervention of chronic diseases.

Entities:  

Keywords:  Low grade inflammation; arginase expression; macrophages; molecular mechanisms

Year:  2013        PMID: 23885329      PMCID: PMC3714206     

Source DB:  PubMed          Journal:  Am J Clin Exp Immunol


  33 in total

Review 1.  Toll-like receptors and innate immunity.

Authors:  S Akira
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

Review 2.  Inflammatory response in Parkinsonism.

Authors:  Carlos Barcia; Francisco Ros; María Angeles Carrillo; David Aguado-Llera; Carmen María Ros; Aurora Gómez; Cristina Nombela; Vicente de Pablos; Emiliano Fernández-Villalba; Maria-Trinidad Herrero
Journal:  J Neural Transm Suppl       Date:  2009

Review 3.  Control of enzyme levels in animal tissues.

Authors:  R T Schimke; D Doyle
Journal:  Annu Rev Biochem       Date:  1970       Impact factor: 23.643

4.  Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease.

Authors:  Dario Sorrentino; Claudio Avellini; Carlo Alberto Beltrami; Enrico Pasqual; Ester Zearo
Journal:  Int J Colorectal Dis       Date:  2005-06-11       Impact factor: 2.571

5.  Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta.

Authors:  Michael J Gray; Mirjana Poljakovic; Diane Kepka-Lenhart; Sidney M Morris
Journal:  Gene       Date:  2005-06-20       Impact factor: 3.688

6.  Low-dose endotoxin induces inflammation by selectively removing nuclear receptors and activating CCAAT/enhancer-binding protein δ.

Authors:  Urmila Maitra; Lu Gan; Samantha Chang; Liwu Li
Journal:  J Immunol       Date:  2011-02-25       Impact factor: 5.422

Review 7.  Alternative activation of macrophages: mechanism and functions.

Authors:  Siamon Gordon; Fernando O Martinez
Journal:  Immunity       Date:  2010-05-28       Impact factor: 31.745

8.  An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2.

Authors:  Urmila Maitra; John S Parks; Liwu Li
Journal:  Mol Cell Biol       Date:  2009-09-14       Impact factor: 4.272

9.  Enhanced skin regeneration by nanoegg formulation of all-trans retinoic acid.

Authors:  Y Yamaguchi; N Nakamura; T Nagasawa; A Kitagawa; K Matsumoto; Y Soma; T Matsuda; M Mizoguchi; R Igarashi
Journal:  Pharmazie       Date:  2006-02       Impact factor: 1.267

10.  Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite.

Authors:  Booki Min; Melanie Prout; Jane Hu-Li; Jinfang Zhu; Dragana Jankovic; Ellen S Morgan; Joseph F Urban; Ann M Dvorak; Fred D Finkelman; Graham LeGros; William E Paul
Journal:  J Exp Med       Date:  2004-08-16       Impact factor: 14.307

View more
  5 in total

1.  All-trans retinoic acid induces arginase-1 and inducible nitric oxide synthase-producing dendritic cells with T cell inhibitory function.

Authors:  Sumantha Bhatt; Jie Qin; Carole Bennett; Shiguang Qian; John J Fung; Thomas A Hamilton; Lina Lu
Journal:  J Immunol       Date:  2014-04-30       Impact factor: 5.422

2.  All Trans Retinoic Acid, Transforming Growth Factor β and Prostaglandin E2 in Mouse Plasma Synergize with Basophil-Secreted Interleukin-4 to M2 Polarize Murine Macrophages.

Authors:  Victor W Ho; Elyse Hofs; Ingrid Elisia; Vivian Lam; Brian E Hsu; June Lai; Beryl Luk; Ismael Samudio; Gerald Krystal
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

3.  All-Trans Retinoic Acid Promotes an M1- to M2-Phenotype Shift and Inhibits Macrophage-Mediated Immunity to Leishmania major.

Authors:  Natália S Vellozo; Sâmara T Pereira-Marques; Mariela P Cabral-Piccin; Alessandra A Filardy; Flávia L Ribeiro-Gomes; Thaís S Rigoni; George A DosReis; Marcela F Lopes
Journal:  Front Immunol       Date:  2017-11-17       Impact factor: 7.561

4.  The Effect of Arginase on Canine T-Lymphocyte Functions and its Modulation by All-Trans Retinoid Acid (ATRA) in Canine Monocyte-Derived Macrophages.

Authors:  Aimee M Soileau; Cally N Quick; Cambri E Moeller; Jessica C Schaumburg; Sita S Withers
Journal:  Vet Sci       Date:  2022-07-21

5.  Stimulation of bovine monocyte-derived macrophages with lipopolysaccharide, interferon-ɣ, Interleukin-4 or Interleukin-13 does not induce detectable changes in nitric oxide or arginase activity.

Authors:  Heather Imrie; Diana J L Williams
Journal:  BMC Vet Res       Date:  2019-01-31       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.